论文部分内容阅读
[目的]研究恶性肿瘤患者血清可溶性转铁蛋白受体(sTfR)和促红细胞生成素(EPO)的水平及化疗对其影响。[方法]采用酶联免疫吸附法和放射免疫分析法分别测定了85例血液系统肿瘤和79例非造血系统肿瘤贫血患者血清sTfR和EPO水平,并对其中36例急性白血病(AL)和41例初治非造血系统肿瘤患者化疗前后血清sTfR和EPO水平进行比较。[结果]血液系统肿瘤和非造血系统肿瘤患者血清EPO水平均明显高于对照组(P<0.05);急性白血病患者化疗后血清sTfR和EPO水平显著高于化疗前(P<0.05),初治非造血系统肿瘤患者化疗后血清sTfR和EPO水平与化疗前相比差异无显著性(P>0.05),化疗后急性白血病患者血清EPO水平明显高于初治非造血系统肿瘤患者(P<0.05)。[结论]恶性肿瘤患者体内内源性EPO水平增高,贫血可能不是由于机体EPO产生不足所致;AL患者化疗前后血清sTfR和EPO水平的变化与骨髓红系造血状况有关,可作为临床化疗效果判定的参考指标。
[Objective] To investigate the serum levels of soluble transferrin receptor (sTfR) and erythropoietin (EPO) in patients with malignant tumor and the effect of chemotherapy. [Methods] Serum levels of sTfR and EPO were measured by ELISA and radioimmunoassay in 85 patients with hematological malignancies and 79 patients with nonhematopoietic anemia. Thirty-six patients with acute leukemia (AL) and 41 The serum levels of sTfR and EPO in patients with newly diagnosed non-hematological malignancies before and after chemotherapy were compared. [Results] The levels of serum EPO in patients with hematological malignancies and those without hematopoietic cancers were significantly higher than those in the control group (P <0.05). The serum levels of sTfR and EPO in patients with acute leukemia after chemotherapy were significantly higher than those before chemotherapy (P <0.05) The levels of serum sTfR and EPO in patients with non-hematopoietic tumors after chemotherapy were not significantly different from those before chemotherapy (P> 0.05). The serum levels of EPO in patients with acute leukemia after chemotherapy were significantly higher than those in patients with newly diagnosed nonhematopoietic tumors (P <0.05) . [Conclusion] The level of endogenous EPO in patients with malignant tumor increased, anemia may not be due to lack of EPO; the changes of serum sTfR and EPO levels in patients with AL before and after chemotherapy are related to hematopoietic status of erythroblasts, which can be used as clinical chemotherapy effect The reference index.